Are epigenetic drugs for diabetes and obesity at our door step?

Drug Discovery Today

Volumn 21, Issue 3, 2016, Pages 499-509

  Arguelles, Andrix O ^a   Meruvu, Sunitha ^a   Bowman, John D ^a   Choudhury, Mahua ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLATING INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR; SIRTUIN ACTIVATING COMPOUND; UNCLASSIFIED DRUG; DNA METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE DEMETHYLASE; SIRTUIN;

DIABETES MELLITUS; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; HUMAN; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; DIABETES MELLITUS; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEMETHYLASES; HUMANS; OBESITY; SIRTUINS;

EID: 84950971713     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.12.001     Document Type: Review

References (93)

1. B.M. Herrera, and et al. Genetics and epigenetics of obesity Maturitas 69 2011 41 49
2. S. Khan, and G.B. Jena Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat Chem. Biol. Interact. 213 2014 1 12
3. D.P. Christensen, and et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus Mol. Med. 17 2011 378 390
4. J. Ye Improving insulin sensitivity with HDAC inhibitor Diabetes 62 2013 685 687
5. S. Chateauvieux, and et al. Molecular and therapeutic potential and toxicity of valproic acid J. Biomed. Biotechnol. 2010 2010 479364
6. V. Belcastro, and et al. Metabolic and endocrine effects of valproic acid chronic treatment Epilepsy Res 107 2013 1 8
7. R. Brown, and et al. Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes Neuroendocrinology 88 2008 25 34
8. L. Qiao, and et al. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid Endocrinology 147 2006 865 874
9. S. Zuo, and et al. Valproic acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none? P T 40 2015 126 132
10. L.B. Avery, and N.N. Bumpus Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice Mol. Pharmacol. 85 2014 1 10
11. B. Viollet, and et al. Cellular and molecular mechanisms of metformin: an overview Clin. Sci. (Lond.) 122 2012 253 270
12. J. Zheng, and et al. Metformin and metabolic diseases: a focus on hepatic aspects Front. Med. 9 2015 173 186
13. T. Iannitti, and B. Palmieri Clinical and experimental applications of sodium phenylbutyrate Drugs R. D. 11 2011 227 249
14. L. Ozcan, and I. Tabas Role of endoplasmic reticulum stress in metabolic disease and other disorders Annu. Rev. Med. 63 2012 317 328
15. S.K. Das, and et al. Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines Am. J. Physiol. Endocrinol. Metab. 295 2008 E393 E400
16. M.F. Gregor, and et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss Diabetes 58 2009 693 700
17. S.E. Choi, and et al. A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS) Arch. Biochem. Biophys. 475 2008 109 114
18. U. Ozcan, and et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 313 2006 1137 1140
19. L. Ozcan, and et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance Cell Metab. 9 2009 35 51
20. Z.F. Luo, and et al. Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation Toxicol. Appl. Pharmacol. 246 2010 49 57
21. W. Qi, and et al. Attenuation of diabetic nephropathy in diabetes rats induced by streptozotocin by regulating the endoplasmic reticulum stress inflammatory response Metabolism 60 2011 594 603
22. C. Xiao, and et al. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans Diabetes 60 2011 918 924
23. S.M. Cabrera, and et al. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes Clin. Exp. Immunol. 172 2013 375 382
24. D.P. Christensen, and et al. Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and beta-cell protection Proc. Natl. Acad. Sci. U. S. A. 111 2014 1055 1059
25. K. Todoerti, and et al. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b Haematologica 95 2010 260 269
26. J. Vojinovic, and N. Damjanov HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis Mol. Med. 17 2011 397 403
27. F. Leoni, and et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo Mol. Med. 11 2005 1 15
28. M. Lundh, and et al. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines Diabetologia 53 2010 2569 2578
29. M.S. Dahllof, and et al. The lysine deacetylase inhibitor Givinostat inhibits beta-cell IL-1beta induced IL-1beta transcription and processing Islets 4 2012 417 422
30. E.C. Lewis, and et al. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro Mol. Med. 17 5-6 2011 369 377
31. S. Reuter, and et al. Epigenetic changes induced by curcumin and other natural compounds Genes Nutr. 6 2011 93 108
32. X.Y. Xie, and et al. Curcumin attenuates lipolysis stimulated by tumor necrosis factor-alpha or isoproterenol in 3T3-L1 adipocytes Phytomedicine 20 2012 3 8
33. D.W. Zhang, and et al. Curcumin and diabetes: a systematic review Evid. Based Complement Alternat. Med. 2013 2013 636053
34. K.-I. Seo, and et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice Mol. Nutr. Food Res. 52 2008 995 1004
35. H.-J. He Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice World J. Diabetes 3 2012 94
36. H. Fujiwara, and et al. Curcumin inhibits glucose production in isolated mice hepatocytes Diabetes Res. Clin. Pract. 80 2008 185 191
37. K. Meghana, and et al. Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role Eur. J. Pharmacol. 577 2007 183 191
38. K. Khalooghi, and et al. In vitro modulation of TCF7L2 gene expression in human pancreatic cells Mol. Biol. Rep. 36 2009 2329 2332
39. L. Shu, and et al. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets Diabetes 57 2008 645 653
40. T. Mrudula, and et al. Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina Biochem. Biophys. Res. Commun. 361 2007 528 532
41. R.A. Kowluru, and M. Kanwar Effects of curcumin on retinal oxidative stress and inflammation in diabetes Nutr. Metab. (Lond.) 4 2007 8
42. K. Tikoo, and et al. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy Br. J. Pharmacol. 153 2008 1225 1231
43. V. Soetikno, and et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-alpha and PKC-beta1 activity in streptozotocin-induced type I diabetic rats Mol. Nutr. Food Res. 55 2011 1655 1665
44. S. Chuengsamarn, and et al. Curcumin extract for prevention of type 2 diabetes Diabetes Care 35 2012 2121 2127
45. J. Wickenberg, and et al. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects Nutr. J. 9 2010 43
46. S. Chuengsamarn, and et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial J. Nutr. Biochem. 25 2014 144 150
47. P. Kuhn, and W. Xu Protein arginine methyltransferases: nuclear receptor coregulators and beyond Prog. Mol. Biol. Transl. Sci. 87 2009 299 342
48. H.S. Han, and et al. Roles of protein arginine methyltransferases in the control of glucose metabolism Endocrinol. Metab. (Seoul) 29 2014 435 440
49. J. Wang, and et al. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation J. Med. Chem. 55 2012 7978 7987
50. H. Iwasaki Impaired PRMT1 activity in the liver and pancreas of type 2 diabetic Goto-Kakizaki rats Life Sci. 85 2009 161 166
51. D. Choi, and et al. Protein arginine methyltransferase 1 regulates hepatic glucose production in a FoxO1-dependent manner Hepatology 56 2012 1546 1556
52. F. Chen, and D.J. Fulton An inhibitor of protein arginine methyltransferases, 7,7′-carbonylbis(azanediyl)bis(4-hydroxynaphthalene-2-sulfonic acid (AMI-1), is a potent scavenger of NADPH-oxidase-derived superoxide Mol. Pharmacol. 77 2010 280 287
53. A. Ojima, and et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression Am. J. Pathol. 182 2013 132 141
54. K.N. Mohan, and J.R. Chaillet Cell and molecular biology of DNA methyltransferase 1 Int. Rev. Cell. Mol. Biol. 306 2013 1 42
55. R.M. Anderson, and et al. Loss of Dnmt1 catalytic activity reveals multiple roles for DNA methylation during pancreas development and regeneration Dev. Biol. 334 2009 213 223
56. U. Ahlgren, and et al. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes Genes Dev. 12 1998 1763 1768
57. B.T. Yang, and et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes Mol. Endocrinol. 26 2012 1203 1212
58. S.E. Pinney, and et al. Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat Diabetologia 54 2011 2606 2614
59. S. Dhawan, and et al. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of Arx Dev. Cell 20 2011 419 429
60. P. Nadkarni, and et al. Regulation of glucose homeostasis by GLP-1 Prog. Mol. Biol. Transl. Sci. 121 2014 23 65
61. E. Hall, and et al. DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets BMC Med. Genet. 14 2013 76
62. N. Singh, and et al. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1 ChemMedChem 4 2009 792 799
63. N. Boon, and et al. The effects of hydralazine on lipolysis in subcutaneous adipose tissue in humans Metabolism 56 2007 1742 1748
64. B.H. Lee, and et al. Procainamide is a specific inhibitor of DNA methyltransferase 1 J. Biol. Chem. 280 2005 40749 40756
65. L. Halby, and et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide ChemBioChem 13 2012 157 165
66. J.M. Foulks, and et al. Epigenetic drug discovery: targeting DNA methyltransferases J. Biomol. Screen. 17 2012 2 17
67. E. Winquist, and et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study Invest. New Drugs 24 2006 159 167
68. S. Asgatay, and et al. Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1 J. Med. Chem. 57 2014 421 434
69. R. Bressler, and et al. Tranylcypromine: a potent insulin secretagogue and hypoglycemic agent Diabetes 17 1968 617 624
70. H.O. Buschiazzo, and et al. Preventive action of tranylcypromine on alloxan diabetes in rats Diabetes 16 1967 810 812
71. C. Binda, and et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2 J. Am. Chem. Soc. 132 2010 6827 6833
72. D. Pan, and et al. Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation PLoS ONE 8 2013 e66294
73. S. Hino, and et al. FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure Nat. Commun. 3 2012 758
74. K. Chase, and R.P. Sharma Epigenetic developmental programs and adipogenesis: implications for psychotropic induced obesity Epigenetics 8 2013 1133 1140
75. S. Timmers, and et al. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann. N. Y. Acad. Sci. 1290 2013 83 89
76. N.L. Price, and et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function Cell Metab. 15 2012 675 690
77. S. Dash, and et al. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men Arterioscler Thromb. Vasc. Biol. 33 2013 2895 2901
78. L. Qiang, and et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma Cell 150 2012 620 632
79. G. Alberdi, and et al. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats Food Chem. 141 2013 1530 1535
80. A. Gracia, and et al. Fatty acid synthase methylation levels in adipose tissue: effects of an obesogenic diet and phenol compounds Genes Nutr. 9 2014 411
81. J.L. Fiori, and et al. Resveratrol prevents beta-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet Diabetes 62 2013 3500 3513
82. J.H. Chung Metabolic benefits of inhibiting cAMP-PDEs with resveratrol Adipocyte 1 2012 256 258
83. J.F. Saldanha, and et al. Resveratrol: why is it a promising therapy for chronic kidney disease patients? Oxid. Med. Cell. Longev. 2013 2013 963217
84. F. Xu, and et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-kappaB pathway Int. J. Endocrinol. 2014 2014 289327
85. B. Jiang, and et al. Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione S-transferases Mu in diabetic rats J. Med. Food 16 2013 481 486
86. H. Elbe, and et al. Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats Hum. Exp. Toxicol. 34 2014 100 113
87. T. Mimura, and et al. The role of SIRT1 in ocular aging Exp. Eye Res. 116 2013 17 26
88. R.A. Kowluru, and et al. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy Invest. Ophthalmol. Vis. Sci. 55 2014 5653 5660
89. A. Bruckbauer, and M.B. Zemel Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity Diabetes Metab. Syndr. Obes. 6 2013 93 102
90. K. Liu, and et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials Am. J. Clin. Nutr. 99 2014 1510 1519
91. I.M. Kapetanovic, and et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats Cancer Chemother. Pharmacol. 68 2011 593 601
92. G. Singh, and R.S. Pai In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration J. Pharm. Pharmacol. 66 2014 1062 1076
93. K.P. Goh, and et al. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure Int. J. Sport Nutr. Exerc. Metab. 24 2014 2 13